From Dow Jones & Company:

Several countries are urging the United States to dismantle a cornerstone of its economic success. A proposal is on the table to ensure people in developing countries can access life-saving medicines, but critics warn that it will gut the U.S. biotech industry and deprive future generations of revolutionary treatments. Several countries that pushed for the measure had a surplus of COVID-19 vaccines when the waiver was approved. Waiving IP protections would put U.S. companies’ trade secrets at risk, stifle innovation, and cause job losses in the biotech sector. An expanded IP waiver would also have significant implications for U.S.-China competition.



Read more: Opinion: Sharing COVID therapy secrets is a Trojan horse that would gut U.S. biotech